Citations 3
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds
Larkey, Nicholas E., Ewaisha, Radwa , Lasho, Michael A., Roforth, Matthew M., Granger, Dane, Jerde, Calvin R. , Gorsh, Amy P., Klassen, Stephen A. , Senefeld, Jonathon W. , Joyner, Michael J. , Baumann, N, Theel, Elitza S. , Mills, John R. , Wu, Liang, Gorsh, Amy, Baumann, Nikola A, Theel, Elitza S , Mills, J R , Joyner, Michael J , Senefeld, Jonathon W , Klassen, Stephen A , Wu, Liang Li
Microbiology Spectrum | July 5, 2022 | Volume: 10 | Issue: 4 | Pages: No page available
COVID-19 convalescent plasma (CCP) was one of the first therapeutic options available for the treatment of SARS-CoV-2 infections and continues to be used selectively for immunosuppressed patients. Given the emergence of novel SARS-CoV-2 variants which are resistant to treatment with available monoclonal antibody (MAb) therapy, CCP remains an important therapeutic consideration.
Anti‐Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1
Ζεκερίδου, Αναστασία , Yang, Binxia , Lennon, Vanda A. , Guo, Yong , Lucchinetti, Claudia F. , McKeon, Andrew , Pittock, Sean J. , Zekeridou, Anastasia , Wu, Liang, McKeon, Andrew , Pittock, S J , Yang, Binxia , Wu, Liang Li , Flanagan, Eoin P.
Annals of Neurology | February 12, 2022 | Volume: 91 | Issue: 5 | Pages: 670-675
The antigen specificity of Anti‐Neuronal Nuclear Antibody‐type 3 (ANNA3)‐IgG is unknown. We identified Dachshund‐homolog 1 (DACH1) as the ANNA3 autoantigen and confirmed it by antigen‐specific assays, immunohistochemical colocalization and immune absorption experiments. Patients' median age was 63.5 years (range, 49–88); 67% were female. Neurological manifestations (information available for 30 patients) included one or more of neuropathy, 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7. Evidence of a neoplasm was present in 27 of 30 (90%), most of neuroendocrine lineage. DACH1‐IgG is rare and represents a novel proposed biomarker of neurological autoimmunity and cancer. ANN NEUROL 2022;91:670–675
SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods
Theel, Elitza S. , Gorsh, Amy P., Granger, Dane, Roforth, Matthew M., Jerde, Calvin R. , Lasho, Michael A., Andersen, Kylie J. , Murphy, Brenna M., Harring, Julie, Lake, Douglas F. , Svarovsky, Sergei, Senefeld, Jonathon W. , Carter, Rickey E. , Joyner, Michael J. , Baumann, N, Mills, John R. , Kunze, Katie L. , Wu, Liang, Lasho, Michael, Baumann, Nikola A, Carter, Rickey E , Andersen, Kylie , Joyner, Michael J , Senefeld, Jonathon W , Johnson, Patrick W. , Wu, Liang Li
Journal of Clinical Microbiology | August 18, 2021 | Volume: 59 | Issue: 9 | Pages: No page available
Longitudinal studies assessing durability of the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) humoral immune response have generated conflicting results. This has been proposed to be due to differences in patient populations, the lack of standardized methodologies, and the use of assays that measure distinct aspects of the humoral response.